ASPARAGINASE
Innovative biopharmaceutical with 100% national technology
Asparaginase
BIOBREYER develops a biosuperior biopharmaceutical for the treatment of Acute Lymphoblastic Leukemia. Our Asparaginase molecule is more stable and less immunogenic, having the ability to provide a better quality treatment. We are currently scaling up the production and carrying out pre-clinical trials.
The scaling up of the production process was carried out in order to cover all stages of the process: from the cell bank to the final formulation. We have developed an innovative upstream process and for downstream stages we rely on the consultancy of the company Merck.
The pre-clinical trials are being carried out in partnership with Hospital das Clínicas and the USP School of Medicine and involve experiments with leukemic cells from patients, mice and zebrafish embryos.
LESS ADVERSE EFFECTS
Protein with structural modifications that provide a longer half-life in the bloodstream and lower antibody formation.
100% NATIONAL TECHNOLOGY
All technology related to the molecule and the production process is 100% national.
GLOBAL INNOVATION
Our molecule has unique characteristics that make it different from what is offered on the market.
REQUEST YOUR QUOTATION
Fill out the form below so that our sales team can contact you and offer the best product.
REQUEST YOUR QUOTATION
Fill out the form below so that our sales team can contact you and offer the best product.
Follow us
Follow us
NEED MORE INFORMATION?
Contact us and learn more about our products, projects and team.
NEED MORE INFORMATION?
Contact us and learn more about our products, projects and team.